# Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct03606967/  
OnCo record `nct03606967` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin, durvalumab, gemcitabine, nab-paclitaxel and other drugs in triple-negative breast cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT03606967 by National Cancer Institute (NCI), with a registry enrolment figure of 86 participants, started 2021-04-13 and due to reach its primary completion in 2026-12-30. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Carboplatin; Computed Tomography; Durvalumab; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Nab-paclitaxel; Personalized Synthetic Long Peptide Vaccine; Poly ICLC; Sacituzumab Govitecan; Tremelimumab. Conditions listed: Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT03606967
- Phase: 2
- Setting: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 86

## Sources

- ClinicalTrials.gov NCT03606967: https://clinicaltrials.gov/study/NCT03606967

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03606967.json